NeuroMAPTM v.1.0

Myriad RBM HumanMAPs

NeuroMAP is a quantitative, multiplexed immunoassay service measuring blood-based proteins associated with neurodegenerative disorders including Alzheimer’s disease, Parkinson’s disease, and Multiple Sclerosis.

Please note: Analyte performance is validated for measurement in serum and plasma. If you would like to send CSF or other fluids, please contact our client service department at clientservices@myriadrbm.com for important details.

Click or mouse over biomarkers for more information. Analytes included in this MAP are subject to change.
1. Brain-Derived Neurotrophic Factor2. Clusterin
3. Cystatin-C4. Factor VII
5. Interleukin-1 receptor antagonist6. Matrix Metalloproteinase-3
7. Matrix Metalloproteinase-98. Neuronal Cell Adhesion Molecule
9. Receptor for advanced glycosylation end products10. S100 calcium-binding protein B1
11. Sortilin12. Superoxide Dismutase 1, soluble
13. Vascular Endothelial Growth Factor

1 This assay did not meet performance specifications in EDTA-Plasma and results should be used for information purposes only.

2 This assay did not meet performance specifications in Serum and results should be used for information purposes only.

Intended for Research Use Only.

Serum or plasma Other fluids*
70 µL 500 µL
*Cerebrospinal fluid, urine, tissue culture supernatants,  bronchoalveolar lavage, synovial fluid, tissue extracts, tears, skin washings, etc.

Bibliography

Neurological Disease

2023

Inflammatory CSF profiles and longitudinal development of cognitive decline in sporadic and GBA-associated PD (2023) Stefanie Lerche, Milan Zimmermann, Benjamin Roeben, Isabel Wurster, , Franca Laura Fries, Christian Deuschle, Katharina Waniek, Ingolf Lachmann, Meike Jakobi, Thomas O. Joos, Thomas Knorpp, Nicole Schneiderhan-Marra and Kathrin Brockmann Nature

Peripheral immune cell imbalance is associated with cortical beta-amyloid deposition and longitudinal cognitive decline (2023) Neel H. Mehta, Liangdong Zhou, Yi Li, Laura Beth McIntire, Anna Nordvig, Tracy Butler, Mony de Leon & Gloria C. Chiang Nature
 
Therapy Indications
 

Associations of neuroinflammatory IL-6 and IL-8 with brain atrophy, memory decline, and core AD biomarkers?In cognitively unimpaired older adults (2023) Elettra Capogna, Leiv Otto Watne, ?ystein S?rensen, Carlijn Jamila Guichelaar, Ane Victoria Idland, Nathalie Bodd Halaas, Kaj Blennow, Henrik Zetterberg, Kristine Beate Walhovd, Anders Martin Fjell, Didac Vidal-Pi?eiro Brain Behavior Immunology

Characterization of the central nervous system penetrant and selective purine P2X7 receptor antagonist JNJ-54175446 in patients with major depressive disorder (2023) Kasper Recourt, Peter de Boer, Peter van der Ark, Heike Benes, Joop M A van Gerven, Marc Ceusters, Luc van Nueten, Wayne C Drevets, Anindya Bhatacharya, Michael Browning, Gabriel E Jacobs Translational Psychiatry
 
Therapy Indications
 

Levels of iron and iron-related proteins in Alzheimer's disease: a systematic review and meta-analysis (2023) Lin Gong, Jiahui Sun, Shuyan Cong Journal of Trace Elements in Medicine and Biology
 
Therapy Indications
 

Back To Top

2022

3Repetitive xenon treatment improves post-stroke sensorimotor and neuropsychiatric dysfunction (2022) Dandekar MP, Yin X, Peng T, Devaraj S, Moarles R, McPherson DD, Huang S Journal of Affective Disorders
 
Therapy Indications
 

Cellular and humoral immunity to SARS-CoV-2 infection in multiple sclerosis patients on ocrelizumab and other disease-modifying therapies: a multi-ethnic observational study (2022) Kister I, Patskovsky Y, Curtin R, Pei J, Perdomo K, Rimler Z, Voloshyna I, Samanovic MI, Cornelius AR, Velmurugu Y, Nyovanie S, Kim J, Tardio E, Bacon TE, Zhovtis L, Ryerson LZ, Raut P, Pedotti R, Hawker K, Raposo C, Priest J, Cabatingan M, Winger RC, Mulligan MJ, Krogsgaard M, Silverman GJ medRxiv
 
Therapy Indications
 

Dissection of depression heterogeneity using proteomic clusters (2022) van Haeringen M, Milaneschi Y, Lamers F, Penninx BWJH, Jansen R Psychological Medicine
 
Therapy Indications
 

Platelet-derived growth factor-BB and white matter hyperintensity burden in APOE4 carriers (2022) Arunima Kapoor, Daniel A Nation Cerebral Circulation - Cognition and Behavior
 
Therapy Indications
 

Peripheral lymphocyte signaling pathway deficiencies predict treatment response in first-onset drug-na?ve schizophrenia (2022) Santiago G. Lago, Jakub Tomasik, Geertje F. Rees, Nitin Rustogi, Javier Vazquez-Bourgon, Sergi Papiol, Paula Suarez-Pinilla, Benedicto Crespo-Facorro, Sabine Bahn Brain Behavior and Immunity
 
Therapy Indications
 

Relationship between cerebrospinal fluid neurodegeneration biomarkers and temporal brain atrophy in cognitively healthy older adults (2022) DidacVidal-Pi?eiro, ?ysteinS?rensen, KajBlennow, Elettra Capogna, Nathalie Bodd Halaas, Ane-VictoriaId, Athanasia Monica Mowinckel, Joana Braga Pereira, Leiv Otto Watne, Henrik Zetterberg, Kristine Beate Walhovd, Anders Martin Fjell Neurobiology of Aging
 
Therapy Indications
 

An Exploratory Analysis of Biomarkers of Perihematomal Edema in the CN-105 in Participants with Acute Supratentorial Intracerebral Hemorrhage (CATCH) Trial (2022) Jay B Lusk, Jesse Troy, Nathaniel Nowacki, Peter G Kranz, Maureen Maughan, Daniel T Laskowitz, Michael L James Journal of Stroke and Cerebrovascular Diseases

Childhood trauma and LPS-stimulated inflammation in adulthood: Results from the Netherlands Study of Depression and Anxiety (2022) Ricki M.de Koning, Erika Kuzminskaite, Christiaan H.Vinkers, Erik J. Giltay, Brenda W.J.H.Penninx Brain, Behavior, and Immunity

Sex differences in Alzheimer?s disease: plasma MMP-9 and markers of disease severity (2022) Amaryllis A. Tsiknia, Erin E. Sundermann, Emilie T. Reas, Steven D. Edland, James B. Brewer, Douglas Galasko & Sarah J. Banks Alzheimer's Research & Therapy
 
Therapy Indications
 

Plasma adiponectin levels predict cognitive decline and cortical thinning in mild cognitive impairment with beta-amyloid pathology (2022) Keun You Kim, Junghee Ha, Minae Kim, So Yeon Cho, Hyunjeong Kim & Eosu Kim Alzheimer's Research & Therapy
 
Therapy Indications
 

Interleukin-3 is associated with sTREM2 and mediates the correlation between amyloid-? and tau pathology in Alzheimer?s disease (2022) Zhi-Bo Wang, Ya-Hui Ma1, Yan Sun1, Lan Tan1, Hui-Fu Wang, Jin-Tai Yu and for the Alzheimer?s Disease Neuroimaging Initiative Journal of Neuroinflammation
 
Therapy Indications
 

Hybrid and vaccine-induced immunity against SARS-CoV-2 in MS patients on different disease-modifying therapies (2022) Ilya Kister , Ryan Curtin, Jinglan Pei, Katherine Perdomo, Tamar E. Bacon, Iryna Voloshyna, Annals of Clinical and Translational Neurology
 
Therapy Indications
 

Back To Top

2021

Proteomic correlates of cortical thickness in cognitively normal individuals with normal and abnormal cerebrospinal fluid beta-amyloid 1-42 (2021) Ekblad LL, Visser PJ, Tijims BM, for the Alzheimer's Disease Neuroimaging Initiative Neurobiology of Aging
 
Therapy Indications
 

CSF proteomic Alzheimer's disease-predictive subtypes in cognitively intact amyloid negative individuals (2021) Tijms BM, Gobom J, Teunissen C, Dobricic V, Tsolaki M, Verhey F, Popp J, Martinex-Lage P, Vandenberghe R, Lleo A, Luis-Molineuvo J, Engelborghs S, Freund-Levi Y, Foelich L, Bertram L, Lovestone S, Streffer J, Vos S, ADNI, Blennow K, Scheltens P, Zetterberg H, Jelle Visser P Proteomes
 
Therapy Indications
 

Assessment of advanced glycation end products and receptors and the risk of dementia (2021) Chen J, Mooldijk SS, Licher S, Waqas K, Ikram MK, Uitterlinden AG, Zillikens MC, Ikram MA JAMA Network Open
 
Therapy Indications
 

TNFRSF1B gene variants and related soluble TNFR2 levels impact reilience in Alzheimer's disease (2021) Pillai JA, Bebek G, Khrestian M, Bena J, Bergmann CC, Bush WS, Leverenz JB, Bekris LM Frontiers in Aging Neuroscience
 
Therapy Indications
 

Identifying associations among genomic, proteomic and imaging biomarkers via adaptive sparse multi-view canonical correlation analysis (2021) Du L, Zhang J, Liu F, Wang H, Guo L, Han J, the Alzheimer's Disease Neuroimaging Initiative Medical Image Analysis
 
Therapy Indications
 

Regional relationships between CSF VEGF levels and Alzheimer's disease brain biomarkers and cognition (2021) Tubi MA, Kothapalli D, Hapenney M, Feingold FW, Mack WJ, King KS, Thompson PM, Braskie MN Neurobiology of Aging
 
Therapy Indications
 

Soluble amyloid-beta isoforms predict downstream Alzheimer's disease pathology (2021) Povala G, Bellaver B, De Bastiani MA, Brum WS, Ferreira PCL, Bieger A, Pascoal TA, Benedet AL, Souza DO, Araujo RM, Zatt B, Rosa-Neto P, Zmmer ER Research Square
 
Therapy Indications
 

Back To Top

2020

Neuroinflammation trajectories precede cognitive impairment after experimental meningitis-evidence from an in vivo PET study. (2020) Giridharan VV, Collodel A, Generoso JS, Scaini G, Wassather R, Selvaraj S, Hasbun R, Dal-Pizzol F, Petronilho F, Barichello T Journal of Neuroinflammation

Cerebrospinal fluid ceruloplasmin levels predict cognitive decline and brain atrophy in people with underlying ?-amyloid pathology (2020) Diouf I, Bush AI, Ayton S Neurobiology of Disease
 
Therapy Indications
 

Phase 1b/2a study of galunisertib, a small molecule inhibitor of transforming growth factor-beta receptor I, in combination with standard temozolomide-based radiochemotherapy in patients with newly diagnosed malignant glioma. (2020) Wick A, Desjardins A, Suarez C, Forsyth P, Gueorguieva I, Burkholder T, Cleverly AL, Estrem ST, Wang S, Lahn MM, Guba SC, Capper D, Rodon J Investigational New Drugs
 
Therapy Indications
 

Degree of Genetic Liability for Alzheimer?s Disease Associated with Specific Proteomic Profiles in Cerebrospinal Fluid (2020) Reus LM, Stringer S, Posthuma D, Teunissen CE, Scheltens P, Pijnenburg YAL, Visser PJ, Tijms BM, for the Alzheimer's Disease Neuroimaging Neurology of Aging
 
Therapy Indications
 

Characterisation of the pharmacodynamic effects of the P2X7 receptor antagonist JNJ-54175446 using an oral dexamphetamine challenge model in healthy males in a randomised, double-blind, placebo-controlled, multiple ascending dose trial. (2020) Recourt K, van der Aart J, Jacobs G, de Kam M, Drevets W, van Nueten L, Kanhal K, Siebenga P, Zuiker R, Ravenstijn P, Timmers M, van Gerven J, de Boer P Journal of Psychopharmacology
 
Therapy Indications
 

Proteomics as a reliable approach for discovery of blood-based Alzheimer's disease biomarkers: a systematic review and meta-analysis. (2020) Rehiman SH, Lim SM, Neoh CF, Majeed ABA, Chin AV, Tan MP, Kamaruzzaman SB, Ramasamy K Ageing Reserch Reviews
 
Therapy Indications
 

APOE e4 genotype-dependent cerebrospinal fluid proteomic signatures in Alzheimer?s disease (2020) Konijnenberg E, Tijms BM, Gobom J, Dobricic V, Bos I, Vos S, Tsolaki M, Verhey F, Popp J, Martinez-Lage P, Vandenberghe R, Lleo A, Frolich L, Lovestone S, Streffer J, Bertram L, Blennow K, Teunissen CE, Veerhuis R, Smit AB, Scheltens P, Zetterberg H, Visser PJ Alzheimer's Research & Therapy
 
Therapy Indications
 

A comprehensive systematic review of CSF proteins and peptides that define Alzheimer?s disease (2020) Pedrero-Prieto CM, Garcia-Carpintero S, Frontinan-Rubio J,Llanos-Gonzalez E, Aguilera Garcia C, Alcain FJ, Lindberg I, Duran-Prado M, Peinado J, Rabanal-Ruiz Y Clinical Proteomics
 
Therapy Indications
 

Proteomic profiling as a diagnotic biomarker for discriminating between bipolar and unipolar depression (2020) Kittel-Schneider S, Hahn T, Haenisch F,McNeill R, Reif A, Bahn S Frontiers in Psychiatry
 
Therapy Indications
 

Elevated plasma cortisol associated with larger ventricles and smaller hippocampal volumes - a study in 2 independent elderly cohorts (2020) Rajagopalan P, Nho K, Risacher SL, Jahanshad N, Boyle CP, Saykin AJ, Thompson PM bioRxiv
 
Therapy Indications
 

Basal and LPS-stimulated inflammatory markers and the course of individual symptoms of depression (2020) van Eeden WA, van Hemert AM, Carlier IVE, Penninx BWJH, Fried EI, Schoevers R, Giltay EJ Translational Psychiatry

Inexpensive, non-invasive biomarkers predict Alzheimer transition using machine learning analysis of the Alzheimer's Disease Neuroimaging (ADNI) database (2020) Beltran JF, Wahba BM, Hose N, Shasha D, Kline RP, ADNI PLoS One
 
Therapy Indications
 

Investigating data-driven biological subtypes of sychiatric disorders using specification-curve analysis (2020) Beijers L, van Loo HM, Romeijn JW, Lamers F, Schoevers RA, Wardenaar KJ Psychological Medicine
 
 

Inflammatory pathway analytes predicting rapid cognitive decline in MCI stage of Alzheimer's disease (2020) Pillai JA, Bena J, Bebek Gurkan, Bekris LM, Bonner-Jackson A, Kou L, Pai A, Sorensen L, Neilsen M, Rao SM, Chance M, Lamb BT, Leverenz JB, Alzheimer's Disease Neuroimaging Initiative Annals of Clinical and Translational Neurology

Basal forebrain degeneration and cortisol as biomarkers mediating Alzheimer's disease pathology: a machine learning approach (2020) Nakirikanti AS Research Thesis
 
Therapy Indications
 

Back To Top

2019

Cortisol associated with hypometabolism across the Alzheimer's disease (2019) Wirth M, Huijbers W, Lange C bioRxiv
 
Therapy Indications
 

SOMAscan-based proteomic measurements of plasma brain natriuretic peptide are decreased in mild cognitive impairment and in Alzheimer's dementia patients (2019) Begic E, Hadzidedic S, Kulaglic A, Ramic-Brkic B, Begic Z, Causevic M PLoS One
 
Therapy Indications
 

A blood-based signature of cerebrospinal fluid A?1-42 status (2019) Goudey B, Fung BJ, Schieber C, Faux NG, Alzheimer's Disease Metabolomics Consortium, Alzheimer's Disease Neuroimaging Initiative Scientific Reports
 
Therapy Indications
 

Maternal deprivation increases microglial activiation and neuroinflammatory markers in the prefrontal cortex and hippocampus of infant rats (2019) Giridharan VV, Gislaine ZR, Selvaraj S, Scaini G, Barichello T, Quevedo J Journal of Psychiatric Research
 
Therapy Indications
 

Applying modern Omic technologies to the Neuronal Ceroid Lipofuscinoses. (2019) Kline RA, Wishart TM, Mills K, Heywood WE BBA - Molecular Basis of Disease
 
Therapy Indications
 

Increased serum levels of leptin and insulin in both schizophrenia and major depressive disorder: A cross-disorder proteomics analysis (2019) Cakici N, Bot M, Lamers F, Janssen T, van der Haan L, Bahn S, Penninx BWJH, van Beveren NJM European Neuropsychopharmacology
 
Therapy Indications
 

Key inflammatory pathway activations in the MCI stage of Alzheimer's disease (2019) Pillai JA, Maxwell S, Bena J, Bekris LM, Rao SM, Chance M, Lamb BT, Leverenz JB Annals of Clinical and Translational Neurology
 
Therapy Indications
 

Plasma cortisol is associated with cerebral hypometabolism across the Alzheimer?s disease spectrum (2019) Wirth M, Lange C, Huijbers W, for the Alzheimer's Disease Neuroimaging Initiative Neurobiology of Aging
 
Therapy Indications
 

Hypothesis: cerebrospinal fluid protein markers suggest a pathway toward symptomatic resilience to AD pathology (2019) Meyer PF, Savard M, Poirier J, Morgan D, Breitner J, for the Alzheimer's Disease Neuroimaging Initiative Alzheimer's & Dementia
 
Therapy Indications
 

The systemic exercise-released chemokine lymphotactin/XCL1 modulates in vitro adult hippocampal precursor cell proliferation and neuronal differentiation. (2019) Leiter O, Bernas SN, Seidemann S, Overall RW, Horenburg C, Kowal S, Kempermann G, Walker TL Scientific Reports

Major depression and enhanced molecular senescence abnormalities in young and middle-aged adults. (2019) Diniz BS, Reynolds Iii CF, Sibille E, Bot M, Penninx BWJH Translational Psychiatry
 
Therapy Indications
 

Innate Immune Cells and C-Reactive Protein in Acute First-Episode Psychosis and Schizophrenia: Relationship to Psychopathology and Treatment (2019) Steiner J, Frodl T, Schiltz K, Dobrowolny H, Jacobs R, Fernandes BS, Guest PC, Meyer-Lotz G, Borucki K, Bahn S, Bogerts B, Falkai P, Bernstein HG Schizophrenia Bulletin

Extracorporeal apheresis therapy for Alzheimer disease-targeting lipids, stress, and inflammation (2019) Bornstein SR, Voit-Bak K, Rosenthal P, Tselmin S, Julius U, Schatz U, Boehm BO, Thuret S, Kempermann G, Reichmann H, Chrousos GP, Licinio J, Wong ML, Schally AV, Straube R Molecular Psychiatry
 
Therapy Indications
 

Blood-based protein mediators of senility with replications across biofluids (2019) Royall DR, Palmer RF, The Alzheimer's Disease Neuroimaging Initiative Brain Communications
 
Therapy Indications
 

Plasma sex hormone-binding globulin predicts neurodegeneration and clinical progression in prodromal Alzheimer's disease (2019) Wu W, Su BJ, Shen XN, Bi YL, Tan CC, Li JQ, Dong Q, Tan L, Alzheimer's Disease Neuroimaging Initiative, Yu JT Cognitive Neuroscience
 
Therapy Indications
 

Back To Top

2018

Allostatic load is associated with psychotic symptoms and decreases withantipsychotic treatment in patients with schizophrenia and ?rst-episodepsychosis (2018) Berger M, Juster RP, Westphal S, Amminger P, Bogerts B, Schiltz K, Bahn S, Steiner J, Sarnyai Z Psychoneuroendocrinology
 
Therapy Indications
 

Evaluation of plasma biomarkers of inflammation in patients with maple syrup urine disease (2018) Scaini G, Tonon T, Moura de Souza CF, Schuck PF, Ferreira GC, Quevedo J, Seda Neto J, Amorim T, Camelo Jr JS, Vitoria Barban Margutti A, Hencke Tresbach R, Sperb-Ludwig F, Boy R, V. de Medeiros PF, Schwards IVD, Luiz Streck E Journal of Inherited Metabolic Disease

Networks of blood proteins in the neuroimmunology of schizophrenia (2018) Jeffries CD, Perkins DO, Fournier M, Do KQ, Cuenod M, Khadimallah I, Domenici E, Addington J, Bearden CE, Cadenhead KS, Cannon TD, Cornblatt BA, Mathalon DH, McGlashan TH, Seidman LJ, Tsuang M, Walker EF, Woods SW Transl Psychiatry
 
 

Testing a multivariate proteomic panel for TBI biomarker discovery: A track-TBI pilot study (2018) Huie JR, Diaz-Arrastia R, Yue JK, Sorani M, Puccio A, Okonkwo DO, Manley GT, Ferguson AR Journal of Neurotrauma

Clinical pharmacokinetics, pharmacodynamics, safety, and tolerability of JNJ-54175446, a brain permeable P2X7 antagonist, in a randomised single-ascending dose study in healthy participants (2018) Timmers M, Ravenstijn P, Xi L, Triana-Baltzer G, Furey M, Van Hemelryck S, Biewenga J, Ceusters M, Bhattacharya A, van den Boer M, van Nueten L, de Boer P Journal of Psychopharmacology
 
Therapy Indications
 

Peripheral immune system in aging and Alzheimer's disease. (2018) Cao W, Zheng H Molecular Neurodegeneartion
 
Therapy Indications
 

Medial Forebrain Bundle Deep Brain Stimulation Reverses Anhedonic-Like Behavior in a Chronic Model of Depression: Importance of BDNF and Inflammatory Cytokines (2018) Dandekar MP, Saxena A, Scaini G, Shin JH, Migut A, Giridharan VV, Zhou Y, Barichello T, Soares JC, Quevedo J, Fenoy AJ Molecular Neurobiology
 
 

Association of baseline inflammatory markers and the development of negative symptoms in individuals at clinical high risk for psychosis (2018) Goldsmith DR, Haroon E, Miller AH, Addington J, Bearden C, Cadenhead K, Cannon T, Cornblatt B, Mathalon D, McGlashan T, Seidman L, Tsunag M, Woods SW, Walker EF, Perkins DO Brain, Behavior, and Immunity

Back To Top

2017

CSF protein changes associated with hippocampal sclerosis risk gene variants highlight impact of GRN/PGRN. (2017) Fardo DW, Katsumata Y, Kauwe JS, Deming Y, Harari O, Cruchaga C; Alzheimer's Disease Neuroimaging Initiative, Nelson PT Exp Gerontol
 
Therapy Indications
 

Few serum proteins mediate APOE?s association with dementia. (2017) Royall DR, Al-Rubaye S, Bishnoi R, Raymond PF PLOS ONE
 
Therapy Indications
 

Fine-mapping of the human leukocyte antigen locus as a risk factor for Alzheimer disease: A case-control study. (2017) Steele NZ, Carr JS, Bonham LS, Geier EG, Damotte V, Miller ZA, Desikan RS, Boehme KL, Mukherjee S, Crane PK, Kauwe JS, Kramer JH, Miller BL, Coppola G, Hollenbach JA, Huang Y, Yokoyama JS PloS Med.
 
Therapy Indications
 

Serum proteins mediate depression?s association with dementia (2017) Royall DR, Al-Rubaye S, Bishnoi R, Palmer RF Plos One
 
Therapy Indications
 

Human umbilical cord plasma proteins revitalize hippocampal function in aged mice. (2017) Castellano JM, Mosher KI, Abbey RJ, McBride AA, James ML, Berdnik D, Shen JC, Zou B, Xie XS, Tingle M, Hinkson IV, Angst MS, Wyss-Coray T Nature
 
Therapy Indications
 

Serum thyroid-stimulating hormone and interleukin-8 levels in boys with autism spectrum disorder (2017) Singh S, Yazdani U, Gadad B, Zaman S, Hynan LS, Roatch N, Schutte C, Marti CN, Hewitson L and German DC J. Neuroinflammation
 
Therapy Indications
 

Exploring hepsin functional genetic variation association with disease specific protein expression in bipolar disorder: Applications of a proteomic informed genomic approach (2017) Nassan M, Jia Y, Jenkins G, Colby C, Feeder S, Choi D, Veldic M, McElroy SL, Bond DJ, Weinshilboum R, Biernacka JM, Frye MA J Psychiatr Res
 
Therapy Indications
 

Neuronal Pentraxin 2 predicts medial temporal atrophy and memory decline across the Alzheimer's disease spectrum. (2017) Swanson A, Willette AA; Alzheimer?s Disease Neuroimaging Initiative. Brain Behav Immun.
 
Therapy Indications
 

Peripheral biomarkers of major depression and antidepressant treatment response: Current knowledge and future outlooks (2017) Gadad BS, Jha MK, Czysz A, Furman JL, Mayes TL, Emslie MP, Trivedi MH J Affect Disord
 
Therapy Indications
 

A multivariate predictive modeling approach reveals a novel CSF peptide signature for both Alzheimer ?s Disease state classification and for predicting future disease progression (2017) Llano DA, Bundela S, Mudar RA, Devanarayan V Plos One
 
Therapy Indications
 

Assessment of Proteomic Measures Across Serious Psychiatric Illness. (2017) Schulz SC, Overgaard S, Bond DJ, Kaldate R. Clin Schizophr Relat Psychoses
 
Therapy Indications
 

Intrathecal 2-hydroxypropyl-?-cyclodextrin decreases neurological disease progression in Niemann-Pick disease, type C1: a non-randomised, open-label, phase 1-2 trial. (2017) Ory DS, Ottinger EA, Farhat NY, King KA, Jiang X, Weissfeld L, Berry-Kravis E, Davidson CD, Bianconi S, Keener LA, Rao R, Soldatos A, Sidhu R, Walters KA, Xu X, Thurm A, Solomon B, Pavan WJ, Machielse BN, Kao M, Silber SA, McKew JC, Brewer CC, Vite CH, Walkley SU, Austin CP, Porter FD Lancet
 
Therapy Indications
 

Glial cells are functionally impaired in juvenile neuronal ceroid lipofuscinosis and detrimental to neurons. (2017) Parviainen L, Dihanich S, Anderson GW, Wong AM, Brooks HR, Abeti R, Rezaie P, Lalli G, Pope S, Heales SJ, Mitchison HM, Williams BP, Cooper JD Acta Neuropathol Commun.
 
Therapy Indications
 

The role of anxious distress in immune dysregulation in patients with major depressive disorder. (2017) Gaspersz R, Lamers F, Wittenberg G, Beekman ATF, van Hemert AM, Schoevers RA, Penninx BWJH Transl Psychiatry

Back To Top

2016

Cerebrovascular and microglial states are not altered by functional neuroinflammatory gene variant (2016) Felsky D, De Jager PL, Schneider JA, Arfanakis K, Fleischman DA, Arvanitakis Z, Honer WG, Pouget JG, Mizrahi R, Pollock BG, Kennedy JL, Bennett DA, Voineskos AN J Cereb Blood Flow Metab

Baseline results of the NeuroNEXT spinal muscular atrophy infant biomarker study (2016) Kolb SJ, Coffey CS, Yankey JW, Krosschell K, Arnold WD, Rutkove SB, Swoboda KJ, Reyna SP, Sakonju A, Darras BT, Shell R, Kuntz N, Castro D, Iannaccone ST, Parsons J, Connolly AM, Chiriboga CA, McDonald C, Burnette WB, Werner K, Thangarajh M, Shieh PB, Finanger E, Cudkowicz ME, McGovern MM, McNeil DE, Finkel R, Kaye E, Kingsley A, Renusch SR, McGovern VL, Wang X, Zaworski PG, Prior TW, Burghes AH, Bartlett A, Kissel JT Ann Clin Transl Neurol
 
Therapy Indications
 

Serum apolipoprotein E is associated with long-term risk of Alzheimer's disease: the Rotterdam Study (2016) Wolters FJ, Koudstaal PJ, Hofman A, Duijn CM, Ikram MA. Neurosci Lett
 
Therapy Indications
 

Predicting Progression from Mild Cognitive Impairment to Alzheimer's Dementia Using Clinical, MRI, and Plasma Biomarkers via Probabilistic Pattern Classification (2016) Korolev IO, Symonds LL, Bozoki AC; Alzheimer's Disease Neuroimaging Initiative PLoS One
 
Therapy Indications
 

Thrombopoietin is associated with d's intercept, and only in Non-Hispanic Whites (2016) Royall DR, Palmer RF Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring
 
Therapy Indications
 

System-Based Proteomic and Metabonomic Analysis of the Df(16)a+/- Mouse Identifies Potential Mir-185 Targets and Molecular Pathway Alterations (2016) Wesseling H, Xu B, Want EJ, Holmes E, Guest PC, Karayiorgou M, Gogos JA, Bahn S Molecular Psychiatry
 
Therapy Indications
 

Noninvasive Transcutaneous Vagus Nerve Stimulation Decreases Whole Blood Culture-Derived Cytokines and Chemokines: A Randomized, Blinded, Healthy Control Pilot Trial (2016) Lerman I, Hauger R, Sorkin L, Proudfoot J, Davis B, Huang A, Lam K, Simon B, Baker DG Neuromodulation: Technology at the Neural Interface

Plasma Egf and Cognitive Decline in Parkinson's Disease and Alzheimer's Disease (2016) Lim NS, Swanson CR, Cherng H-R, Unger TL, Xie SX, Weintraub D, Marek K, Stern MB, Siderowf A, Pars Investigators, Alzheimer's Disease Neuroimaging Initiative, Trojanowski JQ, Chen-Plotkin AS Annals of Clinical and Translational Neurology
 
Therapy Indications
 

Apolipoprotein a-I and Paraoxonase-1 Are Potential Blood Biomarkers for Ischemic Stroke Diagnosis (2016) Walsh KB, Hart K, Roll S, Sperling M, Unruh D, Davidson WS, Lindsell CJ, Adeoye O Journal of Stroke and Cerebrovascular Diseases
 
 

High false-positive rate of a putative biomarker test to aid in the diagnosis of schizophrenia (2016) Wehler CA, Preskorn, SH Journal of Clinical Psychiatry
 
Therapy Indications
 

Inflammatory Profile in Lrrk2-Associated Prodromal and Clinical Pd (2016) Brockmann K, Apel A, Schulte C, Schneiderhan-Marra N, Pont-Sunyer C, Vilas D, Ruiz-Martinez J, Langkamp M, Corvol J-C, Cormier F, Knorpp T, Joos TO, Gasser T, Sch?le B, Aasly JO, Foroud T, Marti-Masso JF, Brice A, Tolosa E, Marras C, Berg D, Maetzler W Journal of Neuroinflammation
 
Therapy Indications
 

Cytokine Production Capacity in Depression and Anxiety (2016) Vogelzangs N, De Jonge P, Smit JH, Bahn S, Penninx BW Translational Psychiatry
 
Therapy Indications
 

A Potential Endophenotype for Alzheimer's Disease: Cerebrospinal Fluid Clusterin (2016) Deming Y, Xia J, Cai Y, Lord J, Holmans P, Bertelsen S, Holtzman D, Morris JC, Bales K, Pickering EH, Kauwe J, Goate A, Cruchaga C Neurobiology of Aging
 
Therapy Indications
 

A Semi-Mechanism Approach Based on Mri and Proteomics for Prediction of Conversion from Mild Cognitive Impairment to Alzheimer?s Disease (2016) Liu H, Zhou X, Jiang H, He H, Liu X Scientific Reports
 
Therapy Indications
 

Early Role of Vascular Dysregulation on Late-Onset Alzheimer's Disease Based on Multifactorial Data-Driven Analysis (2016) Iturria-Medina Y, Sotero RC, Toussaint PJ, Mateos-Perez JM, Evans AC, The Alzheimer's Disease Neuroimaging Initiative Nature Communications
 
Therapy Indications
 

Identification of Plexin A4 as a Novel Clusterin Receptor Links Two Alzheimer's Disease Risk Genes (2016) Kang SS, Kurti A, Wojtas A, Baker KE, Liu CC, Kanekiyo T, Deming Y, Cruchaga C, Estus S, Bu G, Fryer JD Human Molecular Genetics
 
Therapy Indications
 

Serum Proteomic Profiles of Depressive Subtypes (2016) Lamers F, Bot M, Jansen R, Chan MK, Cooper JD, Bahn S, Penninx BWJH Translational Psychiatry
 
Therapy Indications
 

Blood-based immune-endocrine biomarkers of treatment response in depression (2016) Chan MK, Cooper JD, Bot M, Birkenhanger TK, Bergink V, Drexhage HA, Steiner J, Rothermundt M, Penninx BWJH, Bahn S Journal of Psychiatric Research
 
Therapy Indications
 

Insulin-like growth factor binding protein-2 interactions with Alzheimer's disease biomarkers. (2016) Lane EM, Hohman TJ, Jefferson AL; Alzheimer?s Disease Neuroimaging Initiative. Brain Imaging Behav
 
Therapy Indications
 

Oxidative stress in drug-na?ve first episode patients with schizophrenia and major depression: effects of disease acuity and potential confounders (2016) Jordan W, Dobrowolny H, Bahn S, Bernstein HG, Brigadski T Eur Arch Psychiatry Clin Neurosci
 
Therapy Indications
 

Serum protein mediators of dementia and aging proper (2016) Royall DR, Al-Rubaye S, Bishnoi R, Palmer RF Aging
 
Therapy Indications
 

Mindfulness-Based Cognitive Therapy Associated with Decreases in C-Reactive Protein in Major Depressive Disorder: A Pilot Study (2016) Eisendrath SJ, Gillung E, Hartzler A, James-Myers M, Wolkowitz O, Sipe W, Ramanatham D, Delucchi K J. Altern. Complement. Med.
 
Therapy Indications
 

Back To Top

2015

Lack of an association of BDNF Val66Met polymorphism and plasma BDNF with hippocampal volume and memory. (2015) Kim A, Fagan AM, Goate AM, Benzinger TL, Morris JC, Head D; Alzheimer?s Disease Neuroimaging Initiative. Cogn Affect Behav Neurosci. 2015 Mar 18. [Epub ahead of print]
 
Therapy Indications
 

Serum IGF-BP2 Strongly Moderates Age?s Effect on Cognition: A MIMIC Analysis. (2015) Royall DR, Bishnoi RJ, Palmer RF Neurobiol. Aging. 14 April 2015. [Epub ahead of print]
 
Therapy Indications
 

Mechanism-based combination treatment dramatically increases therapeutic efficacy in murine globoid cell leukodystrophy. (2015) Hawkins-Salsbury JA, Shea L, Jiang X, Hunter DA, Guzman AM, Reddy AS, Qin EY, Li Y, Gray SJ, Ory DS, Sands MS. J Neurosci. 2015 Apr 22;35(16):6495-505. doi: 10.1523/JNEUROSCI.4199-14.2015.
 
Therapy Indications
 

Plasma BDNF levels associate with Pittsburgh Compound B binding in the brain. (2015) Hwang KS, Lazaris AS, Eastman JA, Teng E, Thompson PM, Gylys KH, Cole GM, Apostolova LG, for the Alzheimers Dement (Amst) 2015 Apr 22. [Epub ahead of print]
 
Therapy Indications
 

Discovery of serum biomarkers predicting development of a subsequent depressive episode in social anxiety disorder. (2015) Gottschalk MG, Cooper JD, Chan MK, Bot M, Penninx BW, Bahn S. Brain Behav Immun. 2015 Apr 28. pii: S0889-1591(15)00118-X. doi: 10.1016/j.bbi.2015.04.011. [Epub ahead of print]
 
Therapy Indications
 

Total testosterone and neuropsychiatric symptoms in elderly men with Alzheimer?s disease. (2015) Hall JR, Wiechmann AR, Cunningham RL, Johnson LA, Edwards M, Barber RC, Singh M, Winter S, O?Bryant SE, and for the Texas Alzheimer?s Research and Care Consortium. Alzheimers Res Ther. 2015; 7(1): 24. Published online 2015 May 1. doi: 10.1186/s13195-015-0107-4
 
Therapy Indications
 

Blood Protein Markers of Neocortical Amyloid-? Burden: A Candidate Study Using SOMAscan Technology. (2015) Voyle N, Baker D2, Burnham SC, Covin A, Zhang Z, Sangurdekar DP, Tan Hehir CA, Bazenet C, Lovestone S, Kiddle S, Dobson RJ. J Alzheimers Dis. 2015 Apr 16. [Epub ahead of print]
 
Therapy Indications
 

Ferritin levels in the cerebrospinal fluid predict Alzheimer's disease outcomes and are regulated by APOE. (2015) Ayton S, Faux NG, Bush AI; Alzheimer's Disease Neuroimaging Initiative. Nat Commun. 2015 May 19;6:6760. doi: 10.1038/ncomms7760.
 
Therapy Indications
 

Hippocampal proteomic and metabonomic abnormalities in neurotransmission, oxidative stress and apoptotic pathways in a chronic phencyclidine rat model. (2015) Wesseling H, Want EJ, Guest PC, Rahmoune H, Holmes E, Bahn S. J Proteome Res. 2015 Jun 4. [Epub ahead of print]
 
Therapy Indications
 

Immunomodulatory Effects of Probiotic Supplementation in Schizophrenia Patients: A Randomized, Placebo-Controlled Trial. (2015) Tomasik J, Yolken RH, Bahn S, Dickerson FB. Biomark Insights. 2015 Jun 1;10:47-54. doi: 10.4137/BMI.S22007. eCollection 2015.
 
Therapy Indications
 

Multiplex immunoassay analysis of plasma shows differences in biomarkers related to manic or mixed mood states in bipolar disorder patients. (2015) Haenisch F, Alsaif M, Guest PC, Rahmoune H, Yolken R, Dickerson F, Bahn S. Journal of Affective Disorders. 2015 Jun 24. doi:10.1016/j.jad.2015.05.065. [Epub ahead of print]
 
Therapy Indications
 

Genetic studies of quantitative MCI and AD phenotypes in ADNI: Progress, opportunities, and plans (2015) Saykin A, Shen L, Xiohui Y, Kim S, Kwangsik N, Risacher SL, Ramanan VK, Foroud T, Faber KM, Sarwar N, Minsie L, Xiaolan H, Soares HD, Potkin S, Thompson PM, Kauwe JSK, Kaddurah-Daouk R, Green RC, Toga AW, Weiner MW Alzheimer's & Dementia
 
Therapy Indications
 

Perspective: The Alzheimer's Disease Neuroimaging Initiative and the role and contributions of the Private Partner Scientific Board (PPSB) (2015) Liu E, Luthman J, Cedarbaum JM, Scmidt ME, Cole PE, Hendrix J, Carillo MC, Jones-Davis D, Tarver E, Novak G, De Santi S, Soares HD, Potter QZ, Siemers E, Schwarz AJ Alzheimer's & Dementia
 
Therapy Indications
 

Identifying amyloid pathology?related cerebrospinal fluid biomarkers for Alzheimer's disease in a multicohort study (2015) Leung YY, Toledo JB, Nefedov A, Polikar R, Raghavan N, Xie SX, Farnum M, Schultz T, Baek Y, Deerlin VV, Hu WT, Holtzman DM, Fagan AM, Perrin RJ, Grossman M, Soares HD, Kling MA, Mailman M, Arnold SE, Narayan VA, Lee VMY, Shaw LM, Baker D, Wittenberg GM, Trojanowski JQ, Wang LS Alzheimer's & Dementia
 
Therapy Indications
 

Angiogenesis Dysregulation in Term Asphyxiated Newborns Treated with Hypothermia (2015) Shaikh H, Boudes E, Khoja Z, Shevell M, Wintermark P PLOS One
 
 

Central and peripheral changes underlying susceptibility and resistance to social defeat stress ? a proteomic profiling study (2015) Stelzhammer V, Ozcan S, Gottschalk MG, Steeb H, Hodes GE, Guest PC, Rahmoune H, Wong EHF, Russo SJ, Bahn S Diagnostics in Neuropsychiatry
 
Therapy Indications
 

A Subset of Cerebrospinal Fluid Proteins from a Multi-Analyte Panel Associated with Brain Atrophy, Disease Classification and Prediction in Alzheimer's Disease. (2015) Khan W, Aguilar C, Kiddle SJ, Doyle O, Thambisetty M, Muehlboeck S, Sattlecker M, Newhouse S, Lovestone S, Dobson R, Giampietro V, Westman E, Simmons A PLoS One
 
Therapy Indications
 

Multianalyte markers of schizophrenia and bipolar disorder: A preliminary study. (2015) Dickerson F, Schroeder J, Stallings C, Origoni A, Bahn S, Yolken R Schizophr Res.

Shared Immune and Repair Markers During Experimental Toxoplasma Chronic Brain Infection and Schizophrenia (2015) Tomasik J, Schultz TL, Kluge W, Yolken RH, Bahn S, Carruthers VB Schizophr Bull

Lipoprotein-associated phospholipase A2, homocysteine, and Alzheimer?s disease (2015) Doody RS, Demirovic J, Ballantyne CM, Chan W, Barber R, Powell S, Pavlik V Alzheimers Dement (Amst)

Evidence for abnormal cytokine expression in Gulf War Illness: A preliminary analysis of daily immune monitoring data (2015) Parkitny L, Middleton S, Baker K, Younger J BMC Immunology

Pretreatment levels of the fatty acid handling proteins H-FABP and CD36 predict response to olanzapine in recent-onset schizophrenia patients (2015) Tomasik J, Schwarz E, Lago SG, Rothermundt M, Leweke FM, van Beveren NJ, Guest PC, Rahmoune H, Steiner J, Bahn S. Brain Behav Immun.
 
Therapy Indications
 

Plasma Biomarkers for Neuronal Ceroid Lipofuscinosis. (2015) Hersrud SL, Geraets RD, Weber KL, Chan CH, Pearce DA FEBS J.

Serum biomarkers predictive of depressive episodes in panic disorder (2015) Gottschalk MG, Cooper JD, Chan MK, Bot M, Penninx BWJH, Bahn S Journal of Psychiatric Research
 
Therapy Indications
 

Identification of an age-dependent biomarker signature in children and adolescents with autism spectrum disorders (2015) Ramsey JM, Guest PC, Broek JA, Glennon JC, Rommelse N, Franke B, Rahmoune H, Buitelaar JK, Bahn S. Mol Autism
 
Therapy Indications
 

Integrative proteomic analysis of the NMDA NR1 knockdown mouse model reveals effects on central and peripheral pathways associated with schizophrenia and autism spectrum disorders. (2015) Wesseling H, Guest PC, Lee CM, Wong EH, Rahmoune H, Bahn S Mol Autism.
 
Therapy Indications
 

Feasibility of investigating differential proteomic expression in depression: implications for biomarker development in mood disorders (2015) Frye MA, Nassan M, Jenkins GD, Kung S, Veldic M, Palmer BA, Feeder SE, Tye SJ, Choi DS and Biernacka HM Translational Psychiatry
 
Therapy Indications
 

Comparing biological markers of Alzheimer's disease across blood fraction and platforms: Comparing apples to oranges (2015) O'Bryant SE, Listac S, Rissman RA, Edwards M, Zhang F, Hall J, Zetterberg H, Lovestone S, Gupta V, Graff-Radford N, Martins R, Jeromin A, Waring S, Oh E, King M, Baker L, Hampel H Alzheimers Dement (2015) 1-8
 
Therapy Indications
 

Low Plasma Apoe Levels Are Associated with Smaller Hippocampal Size in the Alzheimer's Disease Neuroimaging Initiative Cohort (2015) Teng E, Chow N, Hwang KS, Thompson PM, Gylys KH, Cole GM, Jack Jr CR, Shaw LM, Trojanowski JQ, Soares HD, Weiner MW, Apostolova LG Dementia and Geriatric Cognitive Disorders
 
Therapy Indications
 

An Adaptive Genetic Algorithm for Selection of Blood-Based Biomarkers for Prediction of Alzheimer's Disease Progression (2015) Vandewater L, Brusic V, Wilson W, Macaulay L, Zhang P BMC Bioinformatics
 
Therapy Indications
 

Progressive Reduction in Cortical Thickness as Psychosis Develops: A Multisite Longitudinal Neuroimaging Study of Youth at Elevated Clinical Risk (2015) Cannon TD, Chung Y, He G, Sun D, Jacobson A, Van Erp TGM, Mcewen S, Addington J, Bearden CE, Cadenhead K, Cornblatt B, Mathalon DH, Mcglashan T, Perkins D, Jeffries C, Seidman LJ, Tsuang M, Walker E, Woods SW, Heinssen R Biological Psychiatry
 
Therapy Indications
 

Plasma Inflammatory Factors Are Associated with Anxiety, Depression, and Cognitive Problems in Adults with and without Methamphetamine Dependence: An Exploratory Protein Array Study (2015) Huckans M, Fuller BE, Chalker ALN, Adams M, Loftis JM Frontiers in Psychiatry
 
Therapy Indications
 

Back To Top

2014

CSF Apo-E levels associate with cognitive decline and MRI changes (2014) Toledo JB, Da X, Weiner MW, Wolk DA, Xie SX, Arnold SE, Davatzikos C, Shaw LM, Trojanowski JQ; For the Alzheimer?s Disease Neuroimaging Initiative Acta Neuropathol. 2014 Jan 3. [Epub ahead of print]
 
Therapy Indications
 

Serum proteomic analysis identifies sex-specific differences in lipid metabolism and inflammation profiles in adults diagnosed with Asperger syndrome (2014) Steeb H, Ramsey JM, Guest PC, Stocki P, Cooper JD, Rahmoune H, Ingudomnukul E, Auyeung B, Ruta L, Baron-Cohen S, Bahn S Mol Autism. 2014 Jan 27;5(1):4

Oxidative Stress, Testosterone, and Cognition among Caucasian and Mexican-American Men with and without Alzheimer's Disease (2014) Cunningham RL1, Singh M1, O'Bryant SE2, Hall JR3, Barber RC J Alzheimers Dis. 2014 Feb 4. [Epub ahead of print]
 
Therapy Indications
 

Phosphorylated tau-A?42 Ratio as a Continuous Trait for Biomarker Discovery for Early-Stage Alzheimer's Disease in Multiplex Immunoassay Panels of Cerebrospinal Fluid. (2014) Harari O, Cruchaga C, Kauwe JS, Ainscough BJ, Bales K, Pickering EH, Bertelsen S, Fagan AM, Holtzman DM, Morris JC, Goate AM; Alzheimer?s Disease Neuroimaging Initiative Biol Psychiatry. 2014 Jan 19. pii: S0006-3223(14)00018-3
 
Therapy Indications
 

Cytokine alterations in first-episode schizophrenia patients before and after antipsychotic treatment (2014) de Witte L, Tomasik J, Schwarz E, Guest PC, Rahmoune H, Kahn RS, Bahn S Schizophr Res. 2014 Feb 26. pii: S0920-9964(14)00071-1
 
Therapy Indications
 

The Impact of APOE Status on Relationship of Biomarkers of Vascular Risk and Systemic Inflammation to Neuropsychiatric Symptoms in Alzheimer's Disease (2014) Hall JR, Wiechmann AR, Johnson LA, Edwards M, Barber RC, Cunningham R, Singh M, O'Bryant SE J Alzheimers Dis. 2014 Feb 20. [Epub ahead of print]
 
Therapy Indications
 

MRI signal and texture features for the prediction of MCI to Alzheimer's disease progression (2014) Mart?nez -Torteya A, Rodr?guez-Rojas J, Celaya-Padilla JM, Galv?n-Tejada JI, Trevi?o V, Tamez-Pe?a JG Proc. SPIE 9035
 
Therapy Indications
 

Evaluation of antidepressant properties of the p38 MAP kinase inhibitor losmapimod (GW856553) in Major Depressive Disorder: Results from two randomised, placebo-controlled, double-blind, multicentre studies using a Bayesian approach (2014) Inamdar A, Merlo-Pich E, Gee M, Makumi C, Mistry P, Robertson J, Steinberg E, Zamuner S, Learned S, Alexander R, Ratti E J Psychopharmacol. 2014 Apr 2. [Epub ahead of print]
 
Therapy Indications
 

Inflammatory Molecular Signature Associated With Infectious Agents in Psychosis (2014) Hayes LN, Severance EG, Leek JT, Gressitt KL, Rohleder C, Coughlin JM, Leweke FM, Yolken RH, Sawa A Schizophr Bull. 2014 Apr 17. [Epub ahead of print]
 
Therapy Indications
 

Altered microglial response to A? plaques in APPPS1-21 mice heterozygous for TREM2 (2014) Ulrich JD, Finn MB, Wang Y, Shen A, Mahan TE, Jiang H, Stewart FR, Piccio L, Colonna M, Holtzman DM Mol Neurodegener. 2014 Jun 3;9(1):20

Low levels of cerebrospinal fluid complement 3 and factor H predict faster cognitive decline in mild cognitive impairment (2014) Toledo JB, Korff A, Shaw LM, Trojanowski JQ, Zhang J Alzheimer's Research & Therapy 2014, 6:36
 
Therapy Indications
 

Total Cholesterol and Neuropsychiatric Symptoms in Alzheimer's Disease: The Impact of Total Cholesterol Level and Gender (2014) Hall JR, Wiechmann AR, Johnson LA, Edwards M, Barber RC, Cunningham R, Singh M, O'Bryant SE Dementia and Geriatric Cognitive Disorders Vol. 38, No. 5-6, 2014
 
Therapy Indications
 

Vitamin D Binding Protein as a Serum Biomarker of Alzheimer's Disease. (2014) Bishnoi RJ, Palmer RF, Royall DR. Journal of Alzheimer's Disease 2014 Jul 30. [Epub ahead of print]
 
Therapy Indications
 

Ethnicity Moderates Dementia's Biomarkers. (2014) Royall DR, Palmer RF Journal of Alzheimer's Disease 2014 Jul 30. [Epub ahead of print]
 
Therapy Indications
 

Are Blood-Based Protein Biomarkers for Alzheimer's Disease also Involved in Other Brain Disorders? A Systematic Review (2014) Chiam JTW, Dobson RJB, Kiddle SJ, Sattlecker M Journal of Alzheimer's Disease 2014 Aug 5; 1875-8908 doi:10.3233/JAD-140816
 
Therapy Indications
 

Evidence for disturbed insulin and growth hormone signaling as potential risk factors in the development of schizophrenia. (2014) van Beveren NJ, Schwarz E, Noll R, Guest PC, Meijer C, de Haan L, Bahn S. Translational Psychiatry 2014 Aug 26;4:e430. doi: 10.1038/tp.2014.52.
 
Therapy Indications
 

Multiplex Screen of Serum Biomarkers in (2014) Statlanda J, Donlin-Smithb CM, Tapscottc SJ, van der Maarel S, Tawil, R Journal of Neuromuscular Diseases DOI 0.3233/JND-140034
 
Therapy Indications
 

An Anti-Neuroinflammatory That Targets Dysregulated Glia Enhances the Efficacy of CNS-Directed Gene Therapy in Murine Infantile Neuronal Ceroid Lipofuscinosis. (2014) Macauley SL, Wong AMS, Shyng C, Augner DP, Dearborn JT, Pearse Y, Roberts MS, Fowler SC, Cooper JD, Watterson DM, Sands MS Journal of Neuroscience 2014 Sep 24;34(39):13077-82. doi: 10.1523/JNEUROSCI.2518-14.2014.
 
Therapy Indications
 

Predicting therapeutic efficacy of intravenous immunoglobulin (IVIG) in individual patients with relapsing remitting multiple sclerosis (RRMS) by functional genomics (2014) Berger T, Jacob C, Haas J, Ransmayr G, Guger M, Zettl UK, Di Pauli F, Taumberger B, Wietek S, Meuer S, Reindl M, Giese T Journal of Neuroimmunology DOI: 10.1016/j.jneuroim.2014.10.001

Genome-Wide Association Study of CSF Levels of 59 Alzheimer's Disease Candidate Proteins: Significant Associations with Proteins Involved in Amyloid Processing and Inflammation (2014) Kauwe JS, Bailey MH, Ridge PG, Perry R, Wadsworth ME, Hoyt KL, Staley LA, Karch CM, Harari O, Cruchaga C, Ainscough BJ, Bales K, Pickering EH, Bertelsen S; Alzheimer's Disease Neuroimaging Initiative, Fagan AM, Holtzman DM, Morris JC, Goate AM PLoS Genet
 
Therapy Indications
 

Plasma leptin levels are not predictive of dementia in patients with mild cognitive impairment. (2014) Oania R, McEvoy LK. Age Ageing. 2014 Oct 27. pii: afu160. [Epub ahead of print]
 
Therapy Indications
 

A targeted multiplexed proteomic investigation identifies ketamine-induced changes in immune markers in rat serum and expression changes in protein kinases/phosphatases in rat brain. (2014) Wesseling H, Rahmoune H, Tricklebank M, Guest PC, Bahn S. J Proteome Res. 2014 Nov 2. [Epub ahead of print]
 
Therapy Indications
 

Multiplexed protein profiling after aneurysmal subarachnoid hemorrhage: Characterization of differential expression patterns in cerebral vasospasm. (2014) Walcott BP, Patel AP, Stapleton CJ, Trivedi RA, Young AM, Ogilvy CS. J Clin Neurosci. 2014 Jul 28. pii: S0967-5868(14)00318-X. doi: 10.1016/j.jocn.2014.06.004. [Epub ahead of print]
 
Therapy Indications
 

FASTKD2 is associated with memory and hippocampal structure in older adults. (2014) Ramanan VK, Nho K, Shen L, Risacher SL, Kim S, McDonald BC, Farlow MR, Foroud TM, Gao S, Soininen H, Kloszewska I, Mecocci P, Tsolaki M, Vellas B, Lovestone S, Aisen PS, Petersen RC, Jack CR Jr, Shaw LM, Trojanowski JQ, Weiner MW, Green RC, Toga AW, De Jager PL, Yu L, Bennett DA, Saykin AJ. Mol Psychiatry. 2014 Nov 11. doi: 10.1038/mp.2014.142. [Epub ahead of print]
 
Therapy Indications
 

Biomarkers of Central Nervous System Inflammation in Infantile and Juvenile Gangliosidoses. (2014) Utz JR, Crutcher T, Schneider J, Sorgen P, Whitley CB. Mol Genet Metab. 2014 Dec 6. pii: S1096-7192(14)00376-X. doi: 10.1016/j.ymgme.2014.11.015. [Epub ahead of print]
 
Therapy Indications
 

Proteomic changes in serum of first onset, antidepressant drug-na?ve major depression patients. (2014) Stelzhammer V, Haenisch F, Chan MK, Cooper JD, Steiner J, Steeb H, Martins-de-Souza D, Rahmoune H, Guest PC, Bahn S. Int J Neuropsychopharmacol. 2014 Oct;17(10):1599-608. doi: 10.1017/S1461145714000819. Epub 2014 Jun 5.
 
Therapy Indications
 

Towards a Psychosis Risk Blood Diagnostic for Persons Experiencing High-Risk Symptoms: Preliminary Results From the NAPLS Project. (2014) Perkins DO, Jeffries CD, Addington J, Bearden CE, Cadenhead KS, Cannon TD, Cornblatt BA, Mathalon DH, McGlashan TH, Seidman LJ, Tsuang MT, Walker EF, Woods SW, Heinssen R. Schizophr Bull. 2014 Aug 6. pii: sbu099. [Epub ahead of print]
 
Therapy Indications
 

Plasma biosignature and brain pathology related to persistent cognitive impairment in late-life depression. (2014) Diniz BS, Sibille E, Ding Y, Tseng G, Aizenstein HJ, Lotrich F, Becker JT, Lopez OL, Lotze MT, Klunk WE, Reynolds CF, Butters MA. Mol Psychiatry. 2014 Aug 5. doi: 10.1038/mp.2014.76. [Epub ahead of print]
 
Therapy Indications
 

Development, manufacturing and characterization of a highly purified, liquid immunoglobulin g preparation from human plasma. (2014) Laursen IA, Blou L, Sullivan JS, Bang P, Balstrup F, Houen G. Transfus Med Hemother. 2014 Jun;41(3):205-12. doi: 10.1159/000357982. Epub 2014 Apr 14.

Candidate Blood Proteome Markers of Alzheimer's Disease Onset and Progression: A Systematic Review and Replication Study (2014) Kiddle SJ, Sattlecker M, Proitsi P, Simmons A, Westman E, Bazenet C, Nelson SK, Williams S, Hodges A, Johnston C, Soininen H, Kloszewska I, Mecocci P, Tsolaki M, Vellas B, Newhouse S, Lovestone S, Dobson RJ Journal of Alzheimer's Disease
 
Therapy Indications
 

Significance of Plasma Adiponectin for Diagnosis, Neurological Severity and Functional Outcome in Ischemic Stroke ? Research for Biomarkers in Ischemic Stroke (Rebios) (2014) Kuwashiro T, Ago T, Kamouchi M, Matsuo R, Hata J, Kuroda J, Fukuda K, Sugimori H, Fukuhara M, Awano H, Isomura T, Suzuki K, Yasaka M, Okada Y, Kiyohara Y, Kitazono T Metabolism
 
Therapy Indications
 

The Role of Clusterin in Amyloid-B-Associated Neurodegeneration (2014) Desikan RS, Thompson WK, Holland D, Hess CP, Brewer JB, Zetterberg H, Blennow K, Andreassen OA, McEvoy LK, Hyman BT, Dale AM JAMA Neurology
 
Therapy Indications
 

Back To Top

2013

The Link Between C-Reactive Protein and Alzheimer's Disease Among Mexican Americans (2013) O'Bryant SE, Johnson L, Edwards M, Soares H, Devous MD, Ross S, Rohlfing G, Hall J J Alzheimers Dis. 2013;34(3):701-6
 
Therapy Indications
 

Biomarkers of Alzheimer's Disease Among Mexican Americans (2013) O'Bryant SE, Xiao G, Edwards M, Devous M, Gupta VB, Martins R, Zhang F, Barber R J Alzheimers Dis. 2013 Jan 11. [Epub ahead of print]
 
Therapy Indications
 

Biomarkers of Vascular Risk, Systemic Inflammation, and Microvascular Pathology and Neuropsychiatric Symptoms in Alzheimer's Disease. (2013) Hall JR, Wiechmann AR, Johnson LA, Edwards M, Barber RC, Winter AS, Singh M, O'Bryant SE. Journal of Alzheimer's Disease
 
Therapy Indications
 

Relationship between Plasma Analytes and SPARE-AD Defined Brain Atrophy Patterns in ADNI (2013) Toledo JB, Da X, Bhatt P, Wolk DA, Arnold SE, Shaw LM, Trojanowski JQ, Davatzikos C PLoS One. 2013;8(2):e55531
 
Therapy Indications
 

Plasma apolipoprotein A1 as a biomarker for parkinson's disease (2013) Qiang JK, Wong YC, Siderowf A, Hurtig HI, Xie SX, Lee VM, Trojanowski JQ, Yearout D, Leverenz J, Montine TJ, Stern M, Mendick S, Jennings D, Zabetian C, Marek K, Chen-Plotkin AS Ann Neurol. 2013 Feb 27
 
Therapy Indications
 

The effects of stress on hypothalamic-pituitary-adrenal (HPA) axis function in subjects with schizophrenia (2013) Guest FL, Martins-de-Souza D, Rahmoune H, Bahn S, Guest PC Rev Psiq Cl?n. 2013;40(1):20-7
 
Therapy Indications
 

SMA-MAP: A Plasma Protein Panel for Spinal Muscular Atrophy (2013) Kobayashi DT, Shi J, Stephen L, Ballard KL, Dewey R, Mapes J, Chung B, McCarthy K, Swoboda KJ, Crawford TO, Li R, Plasterer T, Joyce C; Biomarkers for Spinal Muscular Atrophy Study Group, Chung WK, Kaufmann P, Darras BT, Finkel RS, Sproule DM, Martens WB, McDermott MP, De Vivo DC; Pediatric Neuromuscular Clinical Research Network, Walker MG, Chen KS PLoS ONE 8(4): e60113.
 
Therapy Indications
 

Newborn screening for autism: in search of candidate biomarkers (2013) Mizejewski GJ, Lindau-Shepard B, Pass KA Biomark Med. 2013 Apr;7(2):247-60
 
Therapy Indications
 

Heart-type fatty acid binding protein and vascular endothelial growth factor: cerebrospinal fluid biomarker candidates for Alzheimer?s disease (2013) Guo L, Alexopoulos P, Perneczky R European Archives of Psychiatry and Clinical Neuroscience
 
Therapy Indications
 

RANTES has a potential to play a neuroprotective role in an autocrine/paracrine manner after ischemic stroke (2013) Tokamia H, Ago T, Sugimori H, Kuroda J, Awano H, Suzuki K, Kiyohara Y, Kamouchi M, Kitazono T Brain Research, Available online 18 April 2013
 
Therapy Indications
 

Application of meta-analysis methods for identifying proteomic expression level differences (2013) Amess B, Kluge W, Schwarz E, Haenisch F, Alsaif M, Yolken RH, Leweke FM, Guest PC, Bahn S. Proteomics. 2013 Apr 14.

A blood-based predictor for neocortical A? burden in Alzheimer?s disease: results from the AIBL study (2013) Burnham SC, Faux NG, Wilson W, Laws SM, Ames D, Bedo J, Bush AI, Doecke JD, Ellis KA, Head R, Jones G, Kiiveri H, Martins RN, Rembach A, Rowe CC, Salvado O, Macaulay SL, Masters CL, Villemagne VL; Alzheimer?s Disease Neuroimaging Initiative; Australian Imaging, Biomarkers and Lifestyle Study Research Group Mol Psychiatry. 2013 Apr 30
 
Therapy Indications
 

Human and mouse neuroinflammation markers in Niemann-Pick disease, type C1 (2013) Cologna SM, Cluzeau CV, Yanjanin NM, Blank PS, Dail MK, Siebel S, Toth CL, Wassif CA, Lieberman AP, Porter FD. J Inherit Metab Dis. 2013 May 8.
 
Therapy Indications
 

Clinical and Biochemical Differences in Patients Having Parkinson Disease With vs Without GBA Mutations (2013) Chahine LM, Qiang J, Ashbridge E, Minger J, Yearout D, Horn S, Colcher A, Hurtig HI, Lee V M-Y, Van Deerlin VM, Leverenz JB, Siderowf AD, Trojanowski JQ, Zabetian CP, Chen-Plotkin A JAMA Neurol. 2013;():1-7
 
Therapy Indications
 

Diabetic db/db mice exhibit central nervous system and peripheral molecular alterations as seen in neurological disorders (2013) Ernst A, Sharma AN, Elased KM, Guest PC, Rahmoune H, Bahn S Transl Psychiatry. 2013 May 28;3:e263

CSF protein biomarkers predicting longitudinal reduction of CSF ?-amyloid42 in cognitively healthy elders (2013) Mattsson N, Insel P, Nosheny R, Zetterberg H, Trojanowski JQ, Shaw LM, Tosun D, Weiner M Transl Psychiatry. 2013 Aug 20;3:e293
 
Therapy Indications
 

Investigation of molecular serum profiles associated with predisposition to antipsychotic-induced weight gain (2013) Schwarz E, Steiner J, Guest PC, Bogerts B, Bahn S World J Biol Psychiatry. 2013 Sep 3. [Epub ahead of print]
 
Therapy Indications
 

Interleukin 17F Level and Interferon Beta Response in Patients With Multiple Sclerosis (2013) Hartung HP, Steinman L, Goodin DS, Comi G, Cook S, Filippi M, O'Connor P, Jeffery DR, Kappos L, Axtell R, Knappertz V, Bogumil T, Schwenke S, Croze E, Sandbrink R, Pohl C JAMA Neurol. 2013 Aug 1;70(8):1017-21

Does ethnicity moderate dementia's biomarkers (2013) Royall DR, Palmer RF; Texas Alzheimer's Research and Care Consortium Neurobiol Aging. 2013 Sep 18. pii: S0197-4580(13)00340-0
 
Therapy Indications
 

Effects of cerebrospinal fluid proteins on brain atrophy rates in cognitively healthy older adults (2013) Mattsson N, Insel P, Nosheny R, Trojanowski JQ, Shaw LM, Jack Jr. CR, Tosun D, Weiner M, Alzheimer's Disease Neuroimaging Initiative Neurobiology of Aging, Available online 1 October 2013
 
Therapy Indications
 

Identification of a molecular profile associated with immune status in first onset schizophrenia patients (2013) Herberth M, Rahmoune H, Schwarz E, Koethe D, Harris LW, Kranaster L, Witt SH, Spain M, Barnes A, Schmolz M, Leweke MF, Guest PC, Bahn S Clin Schizophr Relat Psychoses

Impaired glycemia increases disease progression in mild cognitive impairment (2013) Morris JK, Vidoni ED, Honea RA, Burns JM Neurobiology of Aging, Available online 23 October 2013

Maternal hematopoietic TNF, via milk chemokines, programs hippocampal development and memory (2013) Liu B, Zupan B, Laird E, Klein S, Gleason G, Bozinoski M, Gal Toth J, Toth M Nat Neurosci. 2013 Dec 1

Multiplex immunoassay analysis of plasma shows prominent upregulation of growth factor activity pathways linked to GSK3? signaling in bipolar patients (2013) Haenisch F, Alsaif M, Guest PC, Rahmoune H, Dickerson F, Yolken R, Bahn S Journal of Affective Disorders
 
Therapy Indications
 

Multi-analyte profile analysis of plasma immune proteins: altered expression of peripheral immune factors is associated with neuropsychiatric symptom severity in adults with and without chronic hepatitis C virus infection (2013) Huckans M, Fuller BE, Olavarria H, Sasaki AW, Chang M, Flora KD, Kolessar M, Kriz D, Anderson JR, Vandenbark AA, Loftis JM Brain and Behavior

Low Plasma Leptin in Cognitively Impaired ADNI Subjects: Gender Differences and Diagnostic and Therapeutic Potential (2013) Johnston J, Hu W, Fardo D, Greco S, Perry G, Montine T, Trojanowski J, Shaw L, Ashford J, Tezapsidis N, For The Alzheimer's Disease Neuroimaging Initiative Curr Alzheimer Res. 2013 Dec 11. [Epub ahead of print]
 
Therapy Indications
 

Identification of Subgroups of Schizophrenia Patients with Changes in Either Immune or Growth Factor and Hormonal Pathways (2013) Schwarz E, Van Beveren NJM, Ramsey J, Leweke FM, Rothermundt M, Bogerts B, Steiner J, Guest PC, Bahn S Schizophrenia Bulletin
 
Therapy Indications
 

Distinct Molecular Phenotypes in Male and Female Schizophrenia Patients (2013) Ramsey JM, Schwarz E, Guest PC, Van Beveren NJM, Leweke FM, Rothermundt M, Bogerts B, Steiner J, Bahn S PLoS ONE
 
Therapy Indications
 

Back To Top

2012

Metabolic, hormonal and stress-related molecular changes in post-mortem pituitary glands from schizophrenia subjects (2012) Krishnamurthy D, Harris LW, Levin Y, Koutroukides TA, Rahmoune H, Pietsch S, Vanattou-Saifoudine N, Leweke FM, Guest PC, Bahn S World J Biol Psychiatry. 2012 Jan 17. [Epub ahead of print]
 
Therapy Indications
 

Plasma biomarkers of depressive symptoms in older adults (2012) Arnold SE, Xie SX, Leung YY, Wang LS, Kling MA, Han X, Kim EJ, Wolk DA, Bennett DA, Chen-Plotkin A, Grossman M, Hu W, Lee VMY, Mackin RS, Trojanowski JQ, Wilson RS, Shaw LM Translational Psychiatry (2012) 2, e65;
 
Therapy Indications
 

Proteomic approaches to unravel the complexity of schizophrenia (2012) Martins-de-Souza D, Guest PC, Rahmoune H, Bahn S Expert Rev Proteomics. 2012 Feb;9(1):97-108
 
Therapy Indications
 

Identification of blood-based molecular signatures for prediction of response and relapse in schizophrenia patients (2012) Schwarz E, Guest PC, Steiner J, Bogerts B, Bahn S Translational Psychiatry (2012) 2, e82
 
Therapy Indications
 

Multivariate Protein Signatures of Pre-Clinical Alzheimer's Disease in the Alzheimer's Disease Neuroimaging Initiative (ADNI) Plasma Proteome Dataset (2012) Johnstone D, Milward EA, Berretta R, Moscato P PLoS One. 2012;7(4):e34341
 
Therapy Indications
 

Candidate Proteins, Metabolites and Transcripts in the Biomarkers for Spinal Muscular Atrophy (BforSMA) Clinical Study (2012) Finkel RS, Crawford TO, Swoboda KJ, Kaufmann P, Juhasz P, Li X, Guo Y, Li RH, Trachtenberg F, Forrest SJ, Kobayashi DT, Chen KS, Joyce CL, Plasterer T PLoS ONE 7(4): e35462
 
Therapy Indications
 

Biomarkers of Basic Activities of Daily Living in Alzheimer's Disease (2012) Hall JR, Johnson LA, Barber RC, Vo HT, Winter AS, O'Bryant SE J Alzheimers Dis. 2012 May 9. [Epub ahead of print]
 
Therapy Indications
 

Analysis of serum and plasma identifies differences in molecular coverage, measurement variability and candidate biomarker selection (2012) Alsaif M, Guest PC, Schwarz E, Reif A, Kittel-Schneider S, Spain M, Rahmoune H, Bahn S Proteomics Clin Appl. 2012 May 29
 
Therapy Indications
 

Biomarkers and Depressive Symptoms in Older Women with and without Cognitive Impairment (2012) Hall JR, Johnson LA, Vo HT, Barber RC, Winter AS, O?Bryant SE Journal of Behavioral and Brain Science, 2012, 2, 276-281
 
Therapy Indications
 

Plasma apolipoprotein levels are associated with cognitive status and decline in a community cohort of older individuals (2012) Song F, Poljak A, Crawford J, Kochan NA, Wen W, Cameron B, Lux O, Brodaty H, Mather K, Smythe GA, Sachdev PS PLoS One. 2012;7(6):e34078
 
Therapy Indications
 

Plasma signaling proteins in persons at genetic risk for Alzheimer disease: influence of APOE genotype (2012) Ringman JM, Elashoff D, Geschwind DH, Welsh BT, Gylys KH, Lee C, Cummings JL, Cole GM Arch Neurol. 2012 Jun 1;69(6):757-64
 
Therapy Indications
 

Blood-Based Protein Biomarkers for Diagnosis of Alzheimer Disease (2012) Doecke JD, Laws SM, Faux NG, Wilson W, Burnham SC, Lam CP, Mondal A, Bedo J, Bush AI, Brown B, De Ruyck K, Ellis KA, Fowler C, Gupta VB, Head R, Macaulay SL, Pertile K, Rowe CC, Rembach A, Rodrigues M, Rumble R, Szoeke C, Taddei K, Taddei T, Trounson B, Ames D, Masters CL, Martins RN; for the Alzheimer's Disease Neuroimaging Initiative and Australian Imaging Biomarker and Lifestyle Research Group Arch Neurol. 2012 Jul 16:1-8
 
Therapy Indications
 

Cerebrospinal fluid APOE levels, an endophenotype for genetic studies for Alzheimer's disease (2012) Cruchaga C, Kauwe JS, Nowotny P, Bales K, Pickering EH, Mayo K, Bertelsen S, Hinrichs A; the Alzheimer?s Disease Neuroimaging Initiative, Fagan AM, Holtzman DM, Morris JC, Goate AM Hum Mol Genet. 2012 Jul 20. [Epub ahead of print]
 
Therapy Indications
 

Plasma Biomarkers Associated With the Apolipoprotein E Genotype and Alzheimer Disease (2012) Soares HD, Potter WZ, Pickering E, Kuhn M, Immermann FW, Shera DM, Ferm M, Dean RA, Simon AJ, Swenson F, Siuciak JA, Kaplow J, Thambisetty M, Zagouras P, Koroshetz WJ, Wan HI, Trojanowski JQ, Shaw LM; for the Biomarkers Consortium Alzheimer's Disease Plasma Proteomics Project Arch Neurol. 2012 Jul 16:1-8
 
Therapy Indications
 

Serum Granulocyte Colony-Stimulating Factor and Alzheimer's Disease (2012) Barber RC, Edwards MI, Xiao G, Huebinger RM, Diaz-Arrastia R, Wilhelmsen KC, Hall JR, OBryant SE, for the Texas Alzheimer's Research and Care Consortium Dement Geriatr Cogn Disord Extra 2012;2:353-360
 
Therapy Indications
 

The Relation between Inflammation and Neuropsychological Test Performance (2012) Balldin VH, Hall JR, Barber RC, Hynan L, Diaz-Arrastia R, O?Bryant SE International Journal of Alzheimer?s Disease Volume 2012, Article ID 703871
 
Therapy Indications
 

Evaluation of Plasma Proteomic Data for Alzheimer Disease State Classification and for the Prediction of Progression From Mild Cognitive Impairment to Alzheimer Disease (2012) Llano DA, Devanarayan V, Simon AJ; The Alzheimer?s Disease Neuroimaging Initiative (ADNI) Alzheimer Dis Assoc Disord. 2012 Sep 27
 
Therapy Indications
 

Plasma Based Markers of [(11)C] PiB-PET Brain Amyloid Burden (2012) Kiddle SJ, Thambisetty M, Simmons A, Riddoch-Contreras J, Hye A, Westman E, Pike I, Ward M, Johnston C, Lupton MK, Lunnon K, Soininen H, Kloszewska I, Tsolaki M, Vellas B, Mecocci P, Lovestone S, Newhouse S, Dobson R; for the Alzheimers Disease Neuroimaging Initiative PLoS One. 2012;7(9):e44260.
 
Therapy Indications
 

Neuroinflammatory phenotype in early Alzheimer's disease (2012) Sudduth TL, Schmitt FA, Nelson PT, Wilcock DM Neurobiol Aging. 2012 Oct 9. pii: S0197-4580(12)00468-X

Proteomic analysis of the maternal protein restriction rat model for schizophrenia: Identification of translational changes in hormonal signalling pathways and glutamate neurotransmission (2012) Guest PC, Urday S, Ma D, Stelzhammer V, Harris LW, Amess B, Pietsch S, Oheim C, Ozanne SE, Bahn S Proteomics. 2012 Oct 16
 
Therapy Indications
 

Neural progenitor cells regulate microglia functions and activity (2012) Mosher KI, Andres RH, Fukuhara T, Bieri G, Hasegawa-Moriyama M, He Y, Guzman R, Wyss-Coray T Nat Neurosci. 2012 Nov;15(11):1485-7
 
Therapy Indications
 

Associations between gonadotropins, testosterone and ? amyloid in men at risk of Alzheimer's disease (2012) Verdile G, Laws SM, Henley D, Ames D, Bush AI, Ellis KA, Faux NG, Gupta VB, Li QX, Masters CL, Pike KE, Rowe CC, Szoeke C, Taddei K, Villemagne VL, Martins RN Mol Psychiatry. 2012 Oct 23
 
Therapy Indications
 

Quantitative Proteomic Analysis of Niemann-Pick Disease, Type C1 Cerebellum Identifies Protein Biomarkers and Provides Pathological Insight (2012) Cologna SM, Jiang X-S, Backlund PS, Cluzeau CVM, Dail MK, Yanjanin NM, Siebel S, Toth CL, Jun H, Wassif CA, Yergey AL, Porter FD PLoS ONE 7(10): e47845
 
Therapy Indications
 

Anti-apoE immunotherapy inhibits amyloid accumulation in a transgenic mouse model of A? amyloidosis (2012) Kim J, Eltorai AE, Jiang H, Liao F, Verghese PB, Kim J, Stewart FR, Basak JM, Holtzman DM J Exp Med. 2012 Nov 5. [Epub ahead of print]
 
Therapy Indications
 

Cardiovascular risk factors, cortisol, and amyloid-? deposition in Alzheimer's Disease Neuroimaging Initiative (2012) Toledo JB, Toledo E, Weiner MW, Jack CR Jr, Jagust W, Lee VM, Shaw LM, Trojanowski JQ; Alzheimer's Disease Neuroimaging Initiative Alzheimers Dement. 2012 Nov;8(6):483-9
 
 

Mapping creatinine- and cystatin C-related white matter brain deficits in the elderly (2012) Rajagopalan P, Refsum H, Hua X, Toga AW, Jack CR Jr, Weiner MW, Thompson PM; Alzheimer's Disease Neuroimaging Initiative Neurobiol Aging. 2012 Nov 19. pii: S0197-4580(12)00533-7

Adipocytokine signaling is altered in flinders sensitive line rats, and adiponectin correlates in humans with some symptoms of depression (2012) Wilhelm CJ, Choi D, Huckans M, Manthe L, Loftis JM Pharmacol Biochem Behav. 2012 Nov 12. pii: S0091-3057(12)00312-7
 
Therapy Indications
 

Electroconvulsive therapy exerts mainly acute molecular changes in serum of major depressive disorder patients (2012) Stelzhammer V, Guest PC, Rothermundt M, Sondermann C, Michael N, Schwarz E, Rahmoune H, Bahn S Eur Neuropsychopharmacol. 2012 Nov 22. pii: S0924-977X(12)00303-3
 
Therapy Indications
 

Differences in the Association of Peripheral Insulin and Cognitive Function in Non-Diabetic Alzheimer's Disease Cases and Normal Controls (2012) Pavlik V, Massman P, Barber R, Doody R J Alzheimers Dis. 2012 Dec 14. [Epub ahead of print]

Comparison of protein concentrations in serum versus plasma from Alzheimer?s patients (2012) Huebinger RM, Xiao G, Wilhelmsen KC, Diaz-Arrastia R, Zhang F, O?Bryant SE, Barber RC Advances in Alzheimer?s Disease Vol.1, No.3, 51-58 (2012)
 
Therapy Indications
 

Plasma multianalyte profiling in mild cognitive impairment and Alzheimer disease (2012) Hu WT, Holtzman DM, Fagan AM, Shaw LM, Perrin R, Arnold SE, Grossman M, Xiong C, Craig-Schapiro R, Clark CM, Pickering E, Kuhn M, Chen Y, Van Deerlin VM, McCluskey L, Elman L, Karlawish J, Chen-Plotkin A, Hurtig HI, Siderowf A, Swenson F, Lee VM, Morris JC, Trojanowski JQ, Soares H; Alzheimer's Disease Neuroimaging Initiative Neurology. 2012 Aug 28;79(9):897-905
 
Therapy Indications
 

Plasma biomarkers for Alzheimer's disease: much needed but tough to find (2012) Bazenet C, Lovestone S Biomark Med. 2012 Aug;6(4):441-54
 
Therapy Indications
 

Plasma methionine sulfoxide in persons with familial Alzheimer's disease mutations (2012) Ringman JM, Fithian AT, Gylys K, Cummings JL, Coppola G, Elashoff D, Pratico D, Moskovitz J, Bitan G Dement Geriatr Cogn Disord. 2012;33(4):219-25
 
Therapy Indications
 

Back To Top

2011

Peripheral profiling analysis for bipolar disorder reveals markers associated with reduced cell survival (2011) Herberth M, Koethe D, Levin Y, Schwarz E, Krzyszton ND, Schoeffmann S, Ruh H, Rahmoune H, Kranaster L, Schoenborn T, Leweke MF, Guest PC, Bahn S Proteomics 11: 94-105.

Identifying Neuroimaging and Proteomic Biomarkers for MCI and AD via the Elastic Net (2011) Shen L, Kim S, Qi Y, Inlow M, Swaminathan S, Nho K, Wan J, Risacher SL, Shaw LM, Trojanowski JQ, Weiner M, Saykin AJ, ADNI Lecture Notes in Computer Science, 2011, Volume 7012/2011, 27-34
 
Therapy Indications
 

Screening for New Biomarkers for Subcortical Vascular Dementia and Alzheimer?s Disease (2011) ?hrfelt A, Andreasson U, Simon A, Zetterberg H, Edman A, Potter W, Holder D, Devanarayan V, Seeburger J, Smith AD, Blennow K, Wallin A Dement Geriatr Cogn Disord Extra 1: 31?42.
 
Therapy Indications
 

Depression and Brain-Derived Neurotrophic Factor Levels in Alzheimer?s Disease (2011) Hall JR, O?Bryant SE, Johnson L, Barber RC Neuroscience & Medicine, 2, 43-47
 
Therapy Indications
 

Plasma clusterin and the risk of Alzheimer disease (2011) Schrijvers EM, Koudstaal PJ, Hofman A, Breteler MM JAMA. 305: 1322-6
 
Therapy Indications
 

Identification of a biological signature for schizophrenia in serum (2011) Schwarz E, Guest PC, Rahmoune H, Harris LW, Wang L, Leweke FM, Rothermundt M, Bogerts B, Koethe D, Kranaster L, Ohrmann P, Suslow T, McAllister G, Spain M, Barnes A, van Beveren NJ, Baron-Cohen S, Steiner J, Torrey FE, Yolken RH, Bahn S Mol Psychiatry. 2012 May;17(5):494-502
 
Therapy Indications
 

Multiplexed Immunoassay Panel Identifies Novel CSF Biomarkers for Alzheimer's Disease Diagnosis and Prognosis (2011) Craig-Schapiro R, Kuhn M, Xiong C, Pickering EH, Liu J, Misko TP, Perrin RJ, Bales KR, Soares H, Fagan AM, Holtzman DM PLoS One. 2011 Apr 19;6(4):e18850
 
Therapy Indications
 

Early improvement on antipsychotic treatment as a predictor of subsequent response in schizophrenia: analyses from ziprasidone clinical studies (2011) O'Gorman C, Kapur S, Kolluri S, Kane J Hum Psychopharmacol. 2011 Jun 2. [Epub ahead of print]
 
Therapy Indications
 

Early reactions of brain-derived neurotrophic factor in plasma (pBDNF) and outcome to acute antidepressant treatment in patients with Major Depression (2011) Dreim?ller N, Schlicht KF, Wagner S, Peetz D, Borysenko L, Hiemke C, Lieb K, Tadic A Neuropharmacology. 2011 Jul 22. [Epub ahead of print]
 
Therapy Indications
 

Modeling of pathological traits in Alzheimer's disease based on systemic extracellular signaling proteome (2011) Britschgi M, Rufibach K, Bauer Huang SL, Clark CM, Kaye JA, Li G, Peskind ER, Quinn JF, Galasko DR, Wyss-Coray T Mol Cell Proteomics. 2011 Jul 8. [Epub ahead of print]
 
Therapy Indications
 

Loss of the receptor tyrosine kinase Axl leads to enhanced inflammation in the CNS and delayed removal of myelin debris during Experimental Autoimmune Encephalomyelitis (2011) Weinger JG, Brosnan CF, Loudig O, Goldberg MF, Macian F, Arnett HA, Prieto AL, Tsiperson V, Shafit-Zagardo B J Neuroinflammation. 2011 May 15;8:49

Building an integrated neurodegenerative disease database at an academic health center (2011) Xie SX, Baek Y, Grossman M, Arnold SE, Karlawish J, Siderowf A, Hurtig H, Elman L, McCluskey L, Van Deerlin V, Lee VM, Trojanowski JQ Alzheimers Dement. 2011 Jul;7(4):e84-e93
 
Therapy Indications
 

The ageing systemic milieu negatively regulates neurogenesis and cognitive function (2011) Villeda SA, Luo J, Mosher KI, Zou B, Britschgi M, Bieri G, Stan TM, Fainberg N, Ding Z, Eggel A, Lucin KM, Czirr E, Park JS, Couillard-Despr?s S, Aigner L, Li G, Peskind ER, Kaye JA, Quinn JF, Galasko DR, Xie XS, Rando TA, Wyss-Coray T Nature. 2011 Aug 31;477(7362):90-4
 
Therapy Indications
 

Identification of a blood-based biological signature in subjects with psychiatric disorders (2011) Schwarz E, Guest PC, Rahmoune H, Martins-de-Souza D, Niebuhr DW, Weber NS, Cowan DN, Yolken RH, Spain M, Barnes A, Bahn S World J Biol Psychiatry. 2012 Dec;13(8):627-32
 
Therapy Indications
 

Inflammatory signaling in Alzheimer disease and depression (2011) Barber, R Cleveland Clinic Journal of Medicine vol. 78 Suppl 1 S47-S49

Proteomic changes induced by anaesthesia and muscle relaxant treatment prior to electroconvulsive therapy (2011) Stelzhammer V, Rothermundt M, Guest PC, Michael N, Sondermann C, Kluge W, Martins-de-Souza D, Rahmoune H, Bahn S Proteomics Clin Appl. 2011 Oct 17.
 
Therapy Indications
 

Relationship of neurocognitive deficits to diagnosis and symptoms across affective and non-affective psychoses (2011) Lewandowski KE, Cohen BM, Keshavan MS, Ong?r D Schizophr Res. 2011 Oct 11. [Epub ahead of print]
 
Therapy Indications
 

Measurement of A?1-42 in Cerebrospinal Fluid is Influenced by Matrix Effects (2011) Slemmon JR, Meredith J, Guss V, Andreasson U, Andreasen N, Zetterberg H, Blennow K J Neurochem. 2011 Oct 25.
 
Therapy Indications
 

A Longitudinal Analysis of Circulating Stress-Related Proteins and Chronic Ethanol Self-Administration in Cynomolgus Macaques (2011) Helms CM, Messaoudi I, Jeng S, Freeman WM, Vrana KE, Grant KA Alcohol Clin Exp Res. 2011 Dec 5. [Epub ahead of print]
 
Therapy Indications
 

A Blood-Based Screening Tool for Alzheimer's Disease That Spans Serum and Plasma: Findings from TARC and ADNI (2011) O'Bryant SE, Xiao G, Barber R, Huebinger R, Wilhelmsen K, Edwards M, Graff-Radford N, Doody R, Diaz-Arrastia R; for the Texas Alzheimer's Research & Care Consortium; for the Alzheimer's Disease Neuroimaging Initiative PLoS One. 2011;6(12):e28092. Epub 2011 Dec 7.
 
Therapy Indications
 

Biomarkers and Depressive Symptoms in a Sample of Cognitively Intact and Alzheimer?s Disease Elderly Males (2011) Hall JR, Vo HT, Johnson LA, Winter S, Barber RC, O?Bryant SE Neuroscience & Medicine, 2011, 2, 306-312
 
Therapy Indications
 

The role of attenuated astrocyte activation in infantile neuronal ceroid lipofuscinosis (2011) Macauley SL, Pekny M, Sands MS J Neurosci. 2011 Oct 26;31(43):15575-85
 
Therapy Indications
 

Transmembrane tumour necrosis factor is neuroprotective and regulates experimental autoimmune encephalomyelitis via neuronal nuclear factor-kappaB (2011) Taoufik E, Tseveleki V, Chu SY, Tselios T, Karin M, Lassmann H, Szymkowski DE, Probert L Brain. 2011 Sep;134(Pt 9):2722-35

Altered Levels of Circulating Insulin and Other Neuroendocrine Hormones Associated with the Onset of Schizophrenia (2011) Guest PC, Schwarz E, Krishnamurthy D, Harris LW, Leweke FM, Rothermundt M, Van Beveren N, Spain M, Barnes A, Steiner J, Rahmoune H, Bahn S Psychoneuroendocrinology

Back To Top

2010

Plasma epidermal growth factor levels predict cognitive decline in Parkinson disease (2010) Chen-Plotkin AS, Hu WT, Siderowf A, Weintraub D, Goldmann Gross R, Hurtig HI, Xie SX, Arnold SE, Grossman M, Clark CM, Shaw LM, McCluskey L, Elman L, Van Deerlin VM, Lee VM, Soares H, Trojanowski JQ Ann Neurol. Nov 29. [Epub ahead of print]

Magnetic Resonance Imaging Predictors of Treatment Response in First-Episode Schizophrenia (2010) Szeszko PR, Narr KL, Phillips OR, McCormack J, Sevy S, Gunduz-Bruce H, Kane JM, Bilder RM, Robinson DG Schizophr Bull. Nov 17. [Epub ahead of print]
 
Therapy Indications
 

Results of a phase I study in patients suffering from secondary-progressive multiple sclerosis demonstrating the safety of the amino acid copolymer PI-2301 and a possible induction of an anti-inflammatory cytokine response (2010) Kovalchin J, Krieger J, Genova M, Collins K, Augustyniak M, Masci A, Hittinger T, Kuca B, Edan G, Braudeau C, Rimbert M, Patel U, Mascioli E, Zanelli E J Neuroimmunol. 225: 153-63.

A Serum Protein-Based Algorithm for the Detection of Alzheimer Disease (2010) O'Bryant SE, Xiao G, Barber R, Reisch J, Doody R, Fairchild T, Adams P, Waring S, Diaz-Arrastia R; for the Texas Alzheimer's Research Consortium Arch Neurol 67: 1077-1081.
 
Therapy Indications
 

Multiple sclerosis: Identification and clinical evaluation of novel CSF biomarkers (2010) Ottervald J, Franz?n B, Nilsson K, Andersson LI, Khademi M, Eriksson B, Kjellstr?m S, Marko-Varga G, V?gv?ri A, Harris RA, Laurell T, Miliotis T, Matusevicius D, Salter H, Ferm M, Olsson T J Proteomics73: 1117-32.

Biomarker discovery for Alzheimer's disease, frontotemporal lobar degeneration, and Parkinson's disease (2010) Hu WT, Chen-Plotkin A, Arnold SE, Grossman M, Clark CM, Shaw LM, McCluskey L, Elman L, Karlawish J, Hurtig HI, Siderowf A, Lee VM, Soares H, Trojanowski JQ Acta Neuropathol 120: 385-99.
 
Therapy Indications
 

Validation of a Blood-Based Laboratory Test to Aid in the Confirmation of a Diagnosis of Schizophrenia (2010) Schwarz E, Izmailov R, Spain M, Barnes A, Mapes JP, Guest PC, Rahmoune H, Pietsch S, Leweke FM, Rothermundt M, Steiner J, Koethe D, Kranaster L, Ohrmann P, Suslow T, Levin Y, Bogerts B, (JM) van Beveren N, McAllister G, Weber N, Niebuhr D, Cowan D, Yolken RH, Bahn S Biomark Insights5: 39?47.
 
Therapy Indications
 

Novel CSF biomarkers for Alzheimer's disease and mild cognitive impairment (2010) Hu WT, Chen-Plotkin A, Arnold SE, Grossman M, Clark CM, Shaw LM, Pickering E, Kuhn M, Chen Y, McCluskey L, Elman L, Karlawish J, Hurtig HI, Siderowf A, Lee VM, Soares H, Trojanowski JQ Acta Neuropathol 119: 669-678.
 
Therapy Indications
 

Classification of Alcohol Abuse by Plasma Protein Biomarkers. (2010) Freeman WM, Salzberg AC, Gonzales SW, Grant KA, Vrana KE Biol Psychiatry 68: 219-22.
 
Therapy Indications
 

Identification of targeted analyte clusters for studies of schizophrenia. (2010) Cheng TM, Lu YE, Guest PC, Rahmoune H, Harris LW, Wang L, Ma D, Stelzhammer V, Umrania Y, Wayland MT, Li? P, Bahn S Mol Cell Proteomics 9: 510-522.
 
Therapy Indications
 

Decreased C-Reactive Protein Levels in Alzheimer Disease. (2010) O'Bryant SE, Waring SC, Hobson V, Hall JR, Moore CB, Bottiglieri T, Massman P, Diaz-Arrastia R J Geriatr Psychiatry Neurol 23: 49-53.
 
Therapy Indications
 

Plasma protein biomarkers for depression and schizophrenia by multi analyte profiling of case-control collections. (2010) Domenici E, Will? DR, Tozzi F, Prokopenko I, Miller S, McKeown A, Brittain C, Rujescu D, Giegling I, Turck CW, Holsboer F, Bullmore ET, Middleton L, Merlo-Pich E, Alexander RC, Muglia P PLoS ONE 5: e9166.
 
Therapy Indications
 

Individual Differences in Hyperlipidemia and Vitamin E Status in Response to Chronic Alcohol Self-Administration in Cynomolgus Monkeys (2010) Lebold KM, Grant KA, Freeman WM, Wiren KM, Miller GW, Kiley C, Leonard SW, Traber MG Alcohol Clin Exp Res. 2010 Nov 30. [Epub ahead of print]

Novel CSF biomarkers for frontotemporal lobar degenerations (2010) Hu WT, Chen-Plotkin A, Grossman M, Arnold SE, Clark CM, Shaw LM, McCluskey L, Elman L, Hurtig HI, Siderowf A, Lee VM, Soares H, Trojanowski JQ Neurology 75: 2079-86.
 
Therapy Indications
 

Sex-specific serum biomarker patterns in adults with Asperger's syndrome (2010) Schwarz E, Guest PC, Rahmoune H, Wang L, Levin Y, Ingudomnukul E, Ruta L, Kent L, Spain M, Baron-Cohen S, Bahn S Mol Psychiatry. 2010 Sep 28. [Epub ahead of print]
 
Therapy Indications
 

Back To Top

2009

Identifying early markers of Alzheimer's disease using quantitative multiplex proteomic immunoassay panels (2009) Soares HD, Chen Y, Sabbagh M, Roher A, Schrijvers E, Breteler M Ann N Y Acad Sci. 1180 :56-67.
 
Therapy Indications
 

Brain-derived neurotrophic factor levels in Alzheimer's disease. (2009) O'Bryant SE, Hobson V, Hall JR, Waring SC, Chan W, Massman P, Lacritz L, Cullum CM, Diaz-Arrastia R; Texas Alzheimer's Research Consortium J Alzheimers Dis 17: 337-341.
 
Therapy Indications
 

Matrix metalloproteinases during and outside of migraine attacks without aura. (2009) Ashina M, Tvedskov JF, Lipka K, Bilello J, Penkowa M, Olesen J Cephalalgia 30: 303-310.
 
Therapy Indications
 

Back To Top

2008

Rapid microglial response around amyloid pathology after systemic anti-Abeta antibody administration in PDAPP mice. (2008) Koenigsknecht-Talboo J, Meyer-Luehmann M, Parsadanian M, Garcia-Alloza M, Finn MB, Hyman BT, Bacskai BJ, Holtzman DM J Neurosci 28: 14156-14164.
 
Therapy Indications
 

Every Order Starts With a Quote

Thank you for your interest in Myriad RBM's innovative biomarker solutions. Please tell us more about what you would like to order and provide us with your details, so we can get back to you with a quote.